03/07/2018 – The voting details for each resolution are available in the Investor Relations section of the website. Post navigationPreviousPrevious post:Combined General Shareholders’ Meeting held on June 29, 2018NextNext post:Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancerRelated PostsUpdate on the restructuring of the AB Science clinical development department in 201819 December 2018Masitinib phase 3 study in Alzheimer’s disease has completed patient recruitment22 October 2018Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis8 October 2018First half of 2018 revenues1 October 2018Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer23 July 2018Combined General Shareholders’ Meeting held on June 29, 20183 July 2018
Update on the restructuring of the AB Science clinical development department in 201819 December 2018
Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis8 October 2018
Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer23 July 2018